Please login to the form below
OAB
This page shows the latest OAB news and features for those working in and with pharma, biotech and healthcare.
Germany’s IQWiG denies Astellas’ incontinence drug
OAB). This review will be taken into consideration by the Federal Joint Committee (GBA), which will then recommend on whether the drug should be reimbursed on Germany's healthcare system. ... The decision is in contrast to the positive guidance from the
Latest news
-
Astellas uses animated bladder in campaign
The campaign is for overactive bladder (OAB) drug Myrbetriq shows an untreated bladder character constantly interrupting a woman as she goes about her daily activities (see video above or on YouTube). ... The new campaign is aimed at women aged 45-69
-
Astellas gets first OK for prostate drug Vesomni
Urology is a core product franchise for Astellas, with its standalone Harnal (tamsulosin) product for BPH and overactive bladder (OAB) therapy Vesicare (solifenacin) bringing in sales of 67bn yen and 87bn ... The company has already added to its OAB
-
NICE recommends Astellas' Betmiga for overactive bladder
Final draft guidance recommends Vesicare successor
-
Allergan gets US approval for Botox in overactive bladder
OAB caused by neuronal damage, for example as a result of spinal cord injury or multiple sclerosis. ... OAB is a condition in which the bladder squeezes too often or squeezes without warning, leading to urinary incontinence, sudden urgent need to urinate
-
European approval for Astellas' first-in-class bladder drug Betmiga
Astellas' Vesicare is the current OAB market leader and the company has said it expects combined sales of the two drugs to exceed ¥155bn (about $1.7bn) by 2014. ... OAB affects more than 400 million people worldwide and in Europe, while 30-40 per
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Astellas: Ten years young
In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new ... class of OAB treatments to emerge in over 30 years, the
-
Interview: Kay Drake and Naoki Okamura, Astellas
For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Astellas strengthens US and Canadian leadership team
As Sabus leaves from the US, Astellas has promoted Lynn Fenicchia Gerber (pictured left) to US vice president, primary care, where she will lead sales efforts for the OAB, anti-fungal,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
emotive project Decisions in Time wins gold for the Digital solution for congress/symposium at the 2014 PM Digital Media Awards
Other emotive projects OAB Health Economics won silver in the Craft Award – Mobile and Diabetes Voyager won bronze in the Innovation Award – Pushing Boundaries.
-
Award-winning emotive project, Decisions in Time, nominated as a finalist in yet more pharmaceutical awards
Along with emotive projects like Diabetes Voyager and OAB Health Economics and Neil Kumar being nominated for Account Manager of the Year, emotive is a finalist for a total of six
-
emotive client Adam Boucher of Novo Nordisk announced as a finalist for Digital Pioneer at the 2014 PM Digital Awards
OAB Health Economics app has been nominated in the Craft Award – Mobile category. -
-
Neil Kumar announced as a finalist for Account Manager of the Year at the PM Society Digital Media Awards 2014
OAB Health Economics app.
-
emotive is thrilled to be a sponsor of the PM Society’s Digital Media Awards 2014
Craft Award – Mobile for OAB Health Economics.
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
Featured jobs
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Senior Account Director, Healthcare Brand Communications, London
-
Excellent Package
- Project Manager, Medical Communications, Oxford
-
Excellent Salary
- Medical Writer, e-learning/ training, London
-
Excellent Salary
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Senior Programme Executive
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Scientific Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and bebefits
- Project Manager, Medical Communications, London
-
Excellent Salary
- Account Manager – Med Comms – London
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
-
Senior Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
No results were found
- P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit
- Publicis LifeBrands Team win UK young Cannes Lions competition
- Sobi poaches Pfizer’s Fredrick Wetterlundh
- Rigel and Ultragenyx claim approvals for rare drugs
- VCCP Health strengthens client service team
- Is agile working benefiting the employee or the organisation?
PMHub
Rainmaker Healthcare Communications
Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...
Latest intelligence
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
- Unique forum will unite NHS and industry to drive innovation
- HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...
Quick links
Infographics
